BIO 2017: Section 101 raises fundamental policy question, says 3M

The perceived problem with 35 USC section 101 is a “fundamental question of national innovation policy”, claimed Kevin Rhodes, vice president and chief IP counsel at multinational conglomerate 3M.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Blow for Masimo’s fight with Apple as case against US Customs dismissed

29 April 2026 The wearable tech company has had to drop its lawsuit against US Customs and Border Protection, part of the wider, ongoing dispute with Apple over a blood oxygen feature in smart watches.

Americas

Ligand buys biotech in $739m cash deal with litigation sweetener

28 April 2026 Pharma group strikes an all-cash transaction, combining a portfolio expansion with a contingent payment linked to a dispute over a $5 billion drug

Americas

CureVac targets Moderna with 10-patent suit over Spikevax

28 April 2026 BioNTech’s former rival—now part of its company—is seeking to assert its mRNA portfolio against Moderna in a new suit over modifications to the highly fought-over molecule.

More features

Blow for Masimo’s fight with Apple as case against US Customs dismissed

Ligand buys biotech in $739m cash deal with litigation sweetener

CureVac targets Moderna with 10-patent suit over Spikevax

Safeguarding critical IP in a high-risk era: WIPR Trade Secrets West 2026

EU court under pressure to define SPC limits in patent row

Amneal acquires biopharma ahead of $300bn patent wave

Health tech firm sues Nvidia-backed rival over ‘brazen’ theft

Squires refuses to resurrect HydraFacial patent review

BIO 2017: Section 101 raises fundamental policy question, says 3M

More on this story

Editor's picks

Editor's picks

More features